Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan
- 1 February 2018
- journal article
- research article
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 27 (2) , e27-e33
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Idarucizumab for Dabigatran Reversal — Full Cohort AnalysisNew England Journal of Medicine, 2017
- Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart AssociationCirculation, 2017
- Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 casesJournal of Thrombosis and Thrombolysis, 2017
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEuropean Heart Journal, 2016
- Management of Bleeding With Non–Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal AgentsCirculation, 2016
- Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulationCritical Care, 2016
- Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial FibrillationStroke, 2015
- Should Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex) Receive Oral Anticoagulation?JACC, 2015
- Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisalInternational Journal of Cardiology, 2015
- A specific antidote for dabigatran: functional and structural characterizationBlood, 2013